Open AccessChinese patent medicine for functional dyspepsia effects
Author(s) -
Jingjie Wu,
Wei Yao,
Yaoxin Chen,
Yu Lei,
Nierui Huang,
Yingbing Mei
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000027761
Subject(s) - medicine , chinese patent medicine , cochrane library , medline , meta analysis , randomized controlled trial , safer , traditional chinese medicine , web of science , alternative medicine , traditional medicine , medical physics , computer science , pathology , computer security , political science , law
Background: In recent years, many clinical studies have suggested that various Chinese patent medicines have the potential to treat functional dyspepsia (FD). This study aims to conduct a systematic review and Bayesian network meta-analysis to evaluate the effectiveness of different Chinese patent medicines for FD. Methods: A comprehensive retrieval method will be executed in the following databases: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBM), VIP Database, and Wanfang Database. Clinical randomized controlled trials (RCTs) of 9 Chinese patent medicines for FD are searched, and the retrieval time is from inception to October 2021. Three reviewers will screen the RCTs that meet the inclusion criteria and extract the data independently. The outcomes include total clinical efficiency, cure rate, recurrence rate, symptom score, and adverse events. Cochrane risk-of-bias tool will be carried to assess RCTs quality. The “gemtc” package and “rjags” package in R software will be used to manage data within the Bayesian framework. Results: The results can provide relatively objective evidence to evaluate the effectiveness of these 9 Chinese patent medicines in treating FD, which may help clinicians to develop a more effective and safer treatment plan. Conclusion: This study aims to provide new options for Chinese patent medicine treatment of FD in terms of its efficacy and safety.